Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan

The planned spending reduction lowers the company's quarterly LOQTORZI revenue target for covering core cash spending.

Rhea-AI Summary

Coherus Oncology (Nasdaq: CHRS) reported third-quarter 2026 results and announced a strategic prioritization plan reducing headcount by approximately 30%. LOQTORZI revenue reached $14.0 million, up 25% year over year and 3% sequentially. Continuing-operations net loss narrowed to $38.9 million, or $0.25 per diluted share, from $44.5 million, or $0.38 per share.

Development will focus on tagmokitug/toripalimab for esophageal cancer, while other combination cohorts are deprioritized. Coherus plans FDA discussions on a new second-line study and a proposed 700 mg dose. The company expects quarterly core cash spending to fall $6 million–$7 million over the next two quarters, lowering LOQTORZI revenue needed to cover it to $25 million–$30 million from $30 million–$35 million. Cash, equivalents and marketable securities were $83.6 million at September 30, including collections earmarked for $19.6 million of transition-services liabilities.

14 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 11 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointLOQTORZI Q3 revenue reached $14.0 million, up 25% year over year and 3% sequentially.
• Moderate pointContinuing-operations revenue rose to $14.3 million in Q3 from $11.6 million; nine-month revenue reached $40.9 million versus $29.4 million.
• Moderate pointQ3 continuing-operations loss narrowed to $38.9 million, or $0.25 per diluted share, versus $44.5 million, or $0.38.
• Moderate pointNine-month continuing-operations loss narrowed to $109.2 million, or $0.73 per diluted share, versus $136.8 million, or $1.18.
• Moderate pointResearch and development expenses fell to $22.6 million in Q3 from $27.3 million; nine-month expenses fell to $65.6 million from $77.9 million.
• Moderate pointSelling, general and administrative expenses fell to $21.2 million in Q3 from $24.9 million; nine-month expenses fell to $65.3 million from $77.0 million.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Coherus expects $6 million–$7 million less quarterly core cash spending, with benefits realized over the next two quarters.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Esophageal cancer development remains prioritized, with a new second-line tagmokitug/toripalimab study planned.
• Moderate pointQ3 operating cash use declined to $34.019 million from $46.339 million a year earlier.

5 minor points

• Minor point. Forward-looking: it has not happened yet and may not happen.LOQTORZI revenue needed to cover core cash spending is expected at $25 million–$30 million quarterly, previously $30 million–$35 million.
• Minor pointSecond-line esophageal cancer's 700 mg subgroup showed 33.3% confirmed tumor response and 55.6% clinical benefit rates.
• Minor pointSecond-line esophageal cancer interim data showed 5.5 months median progression-free survival, measuring time without disease worsening.
• Minor point. Forward-looking: it has not happened yet and may not happen.Tagmokitug/pasritamig Phase 1b prostate cancer study initiation is expected in fall 2026.
• Minor point. Forward-looking: it has not happened yet and may not happen.Casdozokitug combination Phase 2 liver cancer enrollment is complete; first data are expected in 1H 2027.

Negative

• Moderate pointCash, equivalents and marketable securities fell to $83.6 million from $172.1 million at December 31, 2025.
• Moderate pointNine-month operating cash use increased to $153.995 million from $118.797 million a year earlier.
• Moderate pointConsolidated Q3 net loss widened to $39.334 million from $35.531 million a year earlier.
• Moderate pointConsolidated nine-month results shifted to a $98.292 million net loss from $205.667 million net income.
• Moderate pointStrategic prioritization reduces headcount by approximately 30% and deprioritizes other tagmokitug/toripalimab cohorts.
• Moderate pointTerm loans increased to $52.551 million from $37.051 million at December 31, 2025.

5 minor points

• Minor pointAvailable balances include collections earmarked for $19.6 million of transition-services payables and accrued liabilities.
• Minor point. Forward-looking: it has not happened yet and may not happen.New second-line esophageal study design and proposed 700 mg dose require planned FDA alignment.
• Minor pointDebt extinguishment generated a $3.363 million loss in Q3 2026.
• Minor pointInterest expense rose to $2.781 million in Q3 from $2.325 million; nine-month expense reached $7.290 million versus $6.752 million.
• Minor pointCost of goods sold increased to $4.1 million in Q3 from $3.7 million; nine-month costs reached $12.1 million versus $9.8 million.

News Explained

Interim second-line esophageal-cancer data covered 22 treated patients, of whom 13 were evaluable; the company reported a confirmed response rate of 33.3% and a clinical benefit rate of 55.6%, with data as of October 14, 2026.

Argus 15 min delay 8 alerts

-4.33% vs previous close $0.7822 last price 1.6x rel. volume Open Argus

Details

Market move: CHRS -4.33% vs previous close. Q3 2026 earnings report

$0.75 – $0.85 Day Range

$120.85M Mkt Cap at Last Price

On Nov 9, the day this news came out, the latest delayed price for CHRS is 4.33% below the previous close. Our momentum scanner has recorded 8 alerts for this stock so far that day. The latest delayed price is $0.78. Relative volume is above average at 1.6x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

LOQTORZI net revenue: $14.0 million (+25% year over year) Quarterly core cash burn reduction: $6 million to $7 million per quarter LOQTORZI revenue needed to cover core burn: $25 million to $30 million, down from $30 million to $35 million +5 more

LOQTORZI net revenue

$14.0 million (+25% year over year)

Q3 2026 versus Q3 2025

Quarterly core cash burn reduction

$6 million to $7 million per quarter

Expected over the next two quarters

LOQTORZI revenue needed to cover core burn

$25 million to $30 million, down from $30 million to $35 million

Quarterly revenue thresholds

Treated and evaluable patients

22 treated; 13 evaluable

Interim second-line ESCC/EAC clinical activity

Confirmed ORR

33.3%

Interim second-line ESCC/EAC clinical activity

CBR

55.6%

Interim second-line ESCC/EAC clinical activity

Median progression-free survival

5.5 months

Second-line ESCC/EAC data

Cash, cash equivalents and marketable securities

$83.6 million

As of September 30, 2026, versus $172.1 million at December 31, 2025

Previous Earnings Reports

2 past events · Latest: Aug 05

Same Type 2 events

1. Aug 05

   Q2 earnings report

   24h Move

   -12.8%

   LOQTORZI revenue grew sequentially and net loss from continuing operations narrowed versus prior year.

2. Nov 06

   Q3 earnings report

   24h Move

   -10.1%

   LOQTORZI revenue was $11.2 million; continuing-operations revenue reached $11.6 million.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

clinical benefit rate, overall response rate, progression-free survival, pd-1

4 terms

clinical benefit rate medical

"Clinical Benefit Rate (CBR) was 55.6%"

The clinical benefit rate is the share of patients in a medical study who experience a meaningful positive treatment effect — usually tumor shrinkage, disappearance, or disease staying stable for a set period — rather than their condition worsening. Investors care because it gives a broader picture of a therapy’s real-world usefulness beyond quick responses, like judging how many cars in a road test actually arrive without breaking down, which helps predict commercial and regulatory prospects.

overall response rate medical

"confirmed Overall Response Rate (cORR) was 33.3%"

Overall response rate is the percentage of patients in a clinical study whose measurable disease shrinks or disappears after receiving a treatment. Investors watch it like a product’s “hit rate” because higher response rates can signal a drug’s effectiveness, boost chances of regulatory approval and market demand, and affect a company’s future revenue prospects, similar to how a higher batting average suggests a more reliable player.

progression-free survival medical

"Median Progression-Free Survival was 5.5 months"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

pd-1 medical

"tagmokitug enhance PD-1’s activity"

PD-1 is a protein found on certain immune cells that acts like a brake, signaling the immune system to slow down and avoid damaging healthy tissue. Drugs that block PD-1 release that brake so immune cells can better attack cancer cells; because such therapies can produce large clinical benefits, regulatory approvals, trial outcomes, pricing and market uptake for PD-1 drugs can materially affect a drugmaker’s prospects and investor returns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development – 

– Deprioritize development of tagmokitug/toripalimab in other indications to allocate resources toward advancing the lead indication –

– Right-sizing reduces headcount by ~30%, aligning organization with forward-focused needs –

– Reports LOQTORZI® net revenue of $14.0 million in Q3 2026 –

– Conference call today at 5:00 p.m. Eastern Standard Time –

REDWOOD CITY, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today reported financial results for the third quarter 2026 and provided an overview of recent business highlights.

“The strategic prioritization of esophageal cancer as our best-in-disease focus for tagmokitug, together with the Transition Services Agreement wind-down and the toripalimab process transfer completion, provides an ideal opportunity to right-size the organization and deliver financial benefits that flow directly from this prioritization,” said Denny Lanfear, Chief Executive Officer of Coherus Oncology. “Over the next four or five quarters we will remain intensely focused on growing LOQTORZI market share in relation to chemo-only, an inferior therapeutic approach, and off-label IO, which has not demonstrated standard-of-care level of benefit for patients living with nasopharyngeal carcinoma. We believe this approach can provide a path to financial self-sufficiency.”

“Esophageal cancers constitute difficult-to-treat tumors with significant unmet medical need. The compelling anti-tumor activity observed in both ESCC and EAC tumors suggests that Tregs are a critical driver of resistance. Importantly, we saw tagmokitug enhance PD-1’s activity, demonstrate activity in PD-L1 negative tumors, and rescue PD-1 refractory patients,” said Rosh Dias, M.D., Chief Medical Officer of Coherus Oncology. “Our immediate next step is to align with the FDA on our plans to expand the signal observed in esophageal cancer, with an initial focus on the second-line setting. This represents the fastest path to market in this underserved patient population.”

“The financial benefits of right-sizing the organization and reducing the scope of our forward-focused efforts provide substantial and durable benefits to our operating model,” said Bryan McMichael, Chief Financial Officer of Coherus Oncology. “These benefits will be realized over the next two quarters, lowering our core cash burn by $6 million to $7 million quarterly, which in turn lowers the quarterly LOQTORZI revenues required to cover core burn to $25 million to $30 million, down from $30 million to $35 million, as previously guided.”

RECENT BUSINESS HIGHLIGHTS

LOQTORZI® (toripalimab-tpzi) Commercial Updates

• LOQTORZI revenue for Q3 2026 was $14.0 million, a 25% increase over $11.2 million in Q3 2025, and a 3% increase versus $13.6 million in Q2 2026.
• Demand continued to grow in the third quarter, driven by an increasing number of patients on therapy and increasing treatment duration.
• LOQTORZI remains the only FDA-approved and available treatment in the U.S. for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC). It is the only preferred Category 1 first-line treatment option recommended in combination with cisplatin and gemcitabine and the only preferred subsequent-line treatment recommended by the National Comprehensive Cancer Network® (NCCN).
  
  

ADVANCEMENT OF INNOVATIVE, NEXT-GENERATION ONCOLOGY PIPELINE 

Tagmokitug is a highly selective, cytolytic anti-CCR8 antibody designed to preferentially deplete CCR8-positive regulatory T cells (Tregs) in the tumor microenvironment, with the goal of overcoming immune resistance and enhancing antitumor immune responses. Tagmokitug is being evaluated in the TREGCHECK™ Phase 1b/2a clinical program in combination with toripalimab, with and without chemotherapy. As part of the strategic prioritization plan, Coherus will focus near-term tagmokitug development on esophageal cancer and deprioritize the other tagmokitug-toripalimab cohorts presented during our October 28, 2026, data release. The Company will continue ongoing first-line ESCC and second-line ESCC and EAC indications and pursue regulatory alignment on an expedited development path, initially focused on second-line esophageal cancer.

• Enrollment remains ongoing in the Phase 1b cohorts evaluating tagmokitug in combination with toripalimab with or without chemotherapy in first- and second-line ESCC. The second-line EAC patients were enrolled as part of the upper gastrointestinal adenocarcinoma cohort, which has completed accrual and remains in follow-up.
  
  
• The overall interim clinical activity across second-line ESCC and second-line EAC of 22 treated and 13 evaluable patients demonstrated a confirmed ORR of 33.3% and a CBR of 55.6%. Coherus plans to initiate a new study evaluating tagmokitug in combination with toripalimab in patients with second line esophageal cancer (EAC and ESCC), an area of high unmet medical need. The Company intends to align with the FDA on the design of the new study and the proposed 700 mg dose, with the objective of pursuing an expedited development path.
  
  

Figure 1. Second-line ESCC/EAC waterfall plot from TREGCHECK™ 102 Cohorts A (2L EAC) and B (2L ESCC). In the 700 mg dose sub-group, the Clinical Benefit Rate (CBR) was 55.6% and the confirmed Overall Response Rate (cORR) was 33.3%. Data as of October 14, 2026

Figure 2. Second-line ESCC/EAC swimmer plot from TREGCHECK™ 102 Cohorts A (2L EAC) and B (2L ESCC). Median Progression-Free Survival was 5.5 months. Data as of October 14, 2026

• The Company plans to go forward with the Phase 1b clinical study evaluating tagmokitug in combination with pasritamig, a T-cell engaging bispecific antibody, in patients with metastatic castration-resistant prostate cancer (mCRPC), which is expected to initiate in the fall of 2026.
  
  

Casdozokitug is a first-in-class IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line unresectable hepatocellular carcinoma (uHCC) to assess treatment benefit, safety, and response biomarkers.

• Enrollment in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC is complete and the first data readout is expected in 1H 2027.
  
  

THIRD QUARTER 2026 FINANCIAL RESULTS

Net revenue from continuing operations was $14.3 million and $11.6 million during the three months ended September 30, 2026 and 2025, respectively, and $40.9 million and $29.4 million during the nine months ended September 30, 2026 and 2025, respectively. The increases were driven primarily by volume growth of LOQTORZI.

Cost of goods sold (COGS) from continuing operations was $4.1 million and $3.7 million during the three months ended September 30, 2026 and 2025, respectively, and $12.1 million and $9.8 million during the nine months ended September 30, 2026 and 2025, respectively. The increases were primarily due to volume growth of LOQTORZI.

Research and development (R&D) expenses from continuing operations were $22.6 million and $27.3 million for the three months ended September 30, 2026 and 2025, respectively, and $65.6 million and $77.9 million during the nine months ended September 30, 2026 and 2025, respectively. The decreases were primarily due to savings from reduced headcount, lower infrastructure costs, and lower clinical trial and R&D manufacturing costs.

Selling, general and administrative (SG&A) expenses from continuing operations were $21.2 million and $24.9 million during the three months ended September 30, 2026 and 2025, respectively, and $65.3 million and $77.0 million during the nine months ended September 30, 2026 and 2025, respectively. The decreases were driven primarily by lower headcount and decreased operating costs resulting from Coherus completing the exit from the biosimilar business in 2025.

Net loss from continuing operations for the third quarter of 2026 was $38.9 million, or $(0.25) per share on a diluted basis, compared to $44.5 million, or $(0.38) per share on a diluted basis, for the same period in 2025. Net loss for the nine months ended September 2026 was $109.2 million, or $(0.73) per share on a diluted basis, compared to $136.8 million, or $(1.18) per share on a diluted basis for the same period of 2025.

Non-GAAP net loss from continuing operations for the third quarter of 2026 was $31.2 million, or $(0.20) per share on a diluted basis, compared to $38.9 million, or $(0.33) per share for the same period in 2025. Non-GAAP net loss for the nine months ended September 2026 was $95.3 million, or $(0.64) per share on a diluted basis, compared to $118.8 million, or $(1.02) per share for the same period in 2025. See “Non-GAAP Financial Measures” below for a discussion on how Coherus calculates non-GAAP net loss from continuing operations and a reconciliation to the most directly comparable GAAP measures.

Cash, cash equivalents and marketable securities totaled $83.6 million as of September 30, 2026, compared to $172.1 million as of December 31, 2025. These balances were inclusive of Transition Services Agreement (TSA)-related collections that will be applied to associated TSA payables and accrued liabilities which totaled $19.6 million and $65.1 million as of September 30, 2026 and December 31, 2025, respectively.

Conference Call Information
When: Monday, November 9, 2026, starting at 5:00 p.m. Eastern Standard Time

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BI55798b5af6004203b3a31cfe6dff187e

Webcast: https://edge.media-server.com/mmc/p/qhta3pue

A live and archived webcast will be available on the “Investors” section of the Coherus website at
https://investors.coherus.com/events-presentations

Please dial in 15 minutes early to ensure a timely connection to the call.

About Coherus Oncology 

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting esophageal, liver, and prostate cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M nasopharyngeal carcinoma while advancing the development of its two pipeline candidates in combination with LOQTORZI, and additionally through strategic partnerships. The Company has global rights to both clinical-stage candidates and plans to execute ex-U.S. licensing deals as the clinical data support such transactions.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including gastroesophageal junction, esophageal adenocarcinoma, and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, the ability of Coherus’ innovative oncology pipeline to enhance outcomes for cancer patients; the timing and results of anticipated clinical data results; Coherus’ ability to maintain and grow revenues; the effectiveness of Coherus’ cost reduction plan; and Coherus’ expectations about total addressable opportunity for LOQTORZI and for each of its product candidates.

Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to Coherus’ dependence on an ability to raise funds in the future, which may not be available on acceptable terms or at all; risks related to Coherus’ existing and potential collaboration partners; risks of Coherus’ competitive position with LOQTORZI and its product candidates; risks associated with Coherus’ ability to successfully commercialize and maintain and increase revenues for LOQTORZI; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of Coherus’ regulatory filings; the risk of FDA review issues; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2026 filed with the Securities and Exchange Commission on or about the date of this press release, including the section therein captioned “Risk Factors” and in other documents Coherus files with the Securities and Exchange Commission. Coherus’ results for the fiscal quarter ended September 30, 2026 are not necessarily indicative of its operating results for any future periods.

LOQTORZI®, whether or not appearing in large print or with the trademark symbol, is a registered trademark of Coherus Oncology, Inc.

©2026 Coherus Oncology, Inc. All rights reserved.

Coherus Contact Information:
For Investors & Media:
Carrie Graham
Vice President, Investor Relations and Advocacy
IR@coherus.com

Coherus Oncology, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
Net revenue		$	14,274			$	11,571			$	40,891			$	29,424
Costs and expenses:
Cost of goods sold			4,092				3,721				12,148				9,769
Research and development			22,606				27,252				65,591				77,914
Selling, general and administrative			21,225				24,931				65,283				76,995
Total costs and expenses			47,923				55,904				143,022				164,678
Loss from operations			(33,649	)			(44,333	)			(102,131	)			(135,254	)
Interest expense			(2,781	)			(2,325	)			(7,290	)			(6,752	)
Loss on debt extinguishment			(3,363	)			—				(3,363	)			—
Other income (expense), net			918				2,141				3,627				5,229
Loss from continuing operations before income taxes			(38,875	)			(44,517	)			(109,157	)			(136,777	)
Income tax provision			—				—				—				—
Net loss from continuing operations			(38,875	)			(44,517	)			(109,157	)			(136,777	)
Net income (loss) from discontinued operations, net of tax			(459	)			8,986				10,865				342,444
Net income (loss)		$	(39,334	)		$	(35,531	)		$	(98,292	)		$	205,667
Net loss per share from continuing operations - basic and diluted		$	(0.25	)		$	(0.38	)		$	(0.73	)		$	(1.18	)
Net income (loss) per share from discontinued operations - basic and diluted		$	—			$	0.08			$	0.07			$	2.95
Net income (loss) per share - basic and diluted		$	(0.25	)		$	(0.31	)		$	(0.66	)		$	1.77
Weighted-average number of shares used in computing net income (loss) per share:
Basic and diluted			154,970,687				116,229,170				148,796,665				116,056,247

Coherus Oncology, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)

		September 30,			December 31,
		2026			2025
Assets
Cash and cash equivalents		$	53,487		$	88,879
Investments in marketable securities			30,142			83,246
Trade receivables, net			13,720			17,815
Inventory			14,178			3,172
Intangible assets, net			44,364			46,239
Other assets			15,213			18,992
Total assets		$	171,104		$	258,343
Liabilities and Stockholders’ Equity
Accrued rebates, fees and reserve		$	13,746		$	30,397
TSA payables and accrued liabilities			19,638			65,065
Term loans			52,551			37,051
Other liabilities			59,920			64,816
Total stockholders' equity			25,249			61,014
Total liabilities and stockholders’ equity		$	171,104		$	258,343

Coherus Oncology, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
Cash, cash equivalents and restricted cash at beginning of the period		$	83,163			$	217,156			$	89,119			$	126,250
Net cash used in operating activities			(34,019	)			(46,339	)			(153,995	)			(118,797	)
Purchases of investments in marketable securities			(30,064	)			(68,850	)			(50,349	)			(89,576	)
Proceeds from maturities of investments in marketable securities			22,455				1,650				104,126				1,650
Net cash received related to the Sale Transactions			—				—				—				478,681
Milestone payment to Junshi Biosciences			—				—				—				(12,500	)
Other investing activities, net			—				(27	)			(1,100	)			(330	)
Net cash (used in) provided by investing activities			(7,609	)			(67,227	)			52,677				377,925
Proceeds from 2031 Term Loan, net of discount and issuance costs			52,657				—				52,657				—
Proceeds from issuance of common stock under Public Offering, net of issuance costs			—				—				53,650				—
Partial repayment of Revenue Purchase and Sale Agreement			—				—				—				(47,652	)
Proceeds from purchases under the employee stock purchase plan			—				—				202				188
Repayment and redemption of 2026 Convertible Notes, including transaction costs			—				—				(121	)			(233,185	)
Repayment of 2029 Term Loan, including premiums and fees			(40,661	)			—				(40,661	)			—
Other financing activities, net			50				2				53				(1,137	)
Net cash provided by (used in) financing activities			12,046				2				65,780				(281,786	)
Net decrease in cash, cash equivalents and restricted cash			(29,582	)			(113,564	)			(35,538	)			(22,658	)
Cash, cash equivalents and restricted cash at end of the period		$	53,581			$	103,592			$	53,581			$	103,592

Non-GAAP Financial Measures

To supplement the financial results presented in accordance with GAAP, Coherus has included in this press release non-GAAP net loss from continuing operations, and the related per share measures, which exclude from net loss from continuing operations and the related per share measures, stock-based compensation expense, amortization and impairments of intangible assets, loss on debt extinguishment, and change in fair value of our derivative liabilities. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. Coherus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand Coherus’ business.

Coherus believes that the presentation of these non-GAAP financial measures provides useful supplemental information to, and facilitates additional analysis by, investors. In particular, Coherus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare Coherus’ results from period to period, and to identify operating trends in Coherus’ business. Coherus also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.

Coherus Oncology, Inc.
Reconciliation of GAAP Net Loss from Continuing Operations to Non-GAAP Net Loss from Continuing Operations
(in thousands, except share and per share data)
(unaudited)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
GAAP net loss from continuing operations		$	(38,875	)		$	(44,517	)		$	(109,157	)		$	(136,777	)
Adjustments:
Stock-based compensation expense			3,682				3,322				8,650				13,535
Loss on debt extinguishment			3,363				—				3,363				—
Impairment of out-license asset, net			—				1,646				—				1,646
Change in fair value of derivative liabilities			—				—				—				810
Amortization of intangible assets			625				652				1,875				1,986
Non-GAAP net loss from continuing operations		$	(31,205	)		$	(38,897	)		$	(95,269	)		$	(118,800	)
GAAP
Net loss per share from continuing operations, basic and diluted		$	(0.25	)		$	(0.38	)		$	(0.73	)		$	(1.18	)
Shares used in computing basic and diluted net loss per share			154,970,687				116,229,170				148,796,665				116,056,247
Non-GAAP
Net loss per share from continuing operations, basic and diluted		$	(0.20	)		$	(0.33	)		$	(0.64	)		$	(1.02	)
Shares used in computing basic and diluted net loss per share			154,970,687				116,229,170				148,796,665				116,056,247

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/2155bb6d-d515-4df0-b3ef-f82a9c309e0b
https://www.globenewswire.com/NewsRoom/AttachmentNg/6bb69770-2a60-48b6-ba77-87223fd7a004

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Coherus Oncology changing under its strategic prioritization plan?

Coherus is focusing near-term tagmokitug/toripalimab development on esophageal cancer, deprioritizing other combination cohorts and reducing headcount by approximately 30%. It plans a new second-line esophageal cancer study and intends to seek FDA alignment on the study design and proposed 700 mg dose.

How much did Coherus Oncology's LOQTORZI sales grow in Q3 2026?

LOQTORZI revenue reached $14.0 million, increasing 25% from $11.2 million in Q3 2025 and 3% from $13.6 million in Q2 2026.

Which esophageal cancer trials is Coherus Oncology continuing?

Coherus is continuing first-line and second-line studies in esophageal squamous cell carcinoma and second-line work in esophageal adenocarcinoma. Enrollment remains ongoing in the Phase 1b squamous cell carcinoma cohorts. The upper gastrointestinal adenocarcinoma cohort, which included second-line esophageal adenocarcinoma patients, has completed enrollment and remains in follow-up.

When does Coherus Oncology expect casdozokitug liver cancer trial results?

Coherus expects the first data from its randomized Phase 2 casdozokitug/toripalimab/bevacizumab trial in 1H 2027. Enrollment is complete in the trial evaluating the combination in first-line unresectable hepatocellular carcinoma, a liver cancer that cannot be surgically removed.